President Trump’s executive order seeks to speed up marijuana’s reclassification to Schedule III and boost medical research. In essence, the executive order is a significant step toward integrating medical cannabis into the traditional healthcare system, but for now, it primarily signals an intent to change federal policy rather than providing immediate changes to patient access or legal status. Marijuana remains a Schedule I substance under federal law until the Drug Enforcement Administration (DEA) completes the formal rulemaking process to reschedule it. This process involves a public comment period and an administrative law hearing, which could take several months or longer. Potential Future Impacts If marijuana is successfully moved to Schedule III, medical cannabis patients could see several positive changes: Increased Research and Guidance: Rescheduling would significantly ease barriers for clinical and observational research, allowing scientists to gather more data on safety and efficacy for various conditions. This could lead to more consistent, evidence-based guidance for doctors and safer, better-labeled products for patients. FDA-Approved Treatments and Insurance Coverage: The ultimate goal of rescheduling is to facilitate the development of FDA-approved cannabis-derived medications. Once approved, these treatments could eventually be covered by health insurance benefits, including Medicare and Medicaid, making them more affordable for patients.

Once more research is done to refine and make CBD more potent, it may rival the discovery